Olay Case Study

Late 1990s. Oil of Olay sits at roughly $750 million, flat, with an aging consumer base and a nickname doing real damage. P&G's options: let it die, acquire a prestige brand for the segment, or reinvent. They reinvented, by running the Strategy Choice Cascade with unusual discipline, and the case is worth studying box by box because every answer needs the others.

The five choices

Winning Aspiration: number one skincare brand globally, by creating a segment that did not yet exist, "masstige". Where to Play: women 35 to 50 noticing the first signs of aging, explicitly not the existing 50-plus base, in mass retail, explicitly not department stores. How to Win: science-backed "fight the seven signs of aging", with prestige cues at $18.99 in mass channels, against $3.99 before. Must-have capabilities: R&D partnerships, and an invented role, the "technical marketer", bridging dermatologists and beauty editors. Enabling systems: new talent, metrics and retail-partnership machinery built specifically for masstige.

The result, and the lesson

Roughly 3.3 times revenue, ten-plus per cent annual growth for a decade, category leadership. The lesson is integration: the masstige field only works because of the science-backed way of winning, which only works because of the R&D capabilities, which persist only because of the systems built to sustain them. Remove one link and the chain fails. Rivals could see every choice and copy none of the system.

The under-read detail

The conditions were tested, not assumed. Would women pay $18.99 at mass retail? That is What Would Have to Be True in action: the pivotal doubtful condition identified and tested before the company bet the brand on it. The case reads as bold in retrospect; at the time it was a sequence of examined assumptions.

How this connects to OKRs

The Olay reinvention is what a strategy looks like when it is ready to be executed through quarterly bets: named conditions to test, capabilities to build, customer behaviour to move. Each maps to the classic shapes of strategic cross-functional OKRs. When a strategy cannot generate testable quarters, it has not reached Olay's starting line.

The reading nobody else runs: Olay's OKRs, quarter by quarter

Every strategy site retells Olay. Here is the thing none of them do, because it is the part only a goal practitioner cares about. Martin's account tells you the choices that were made; it does not tell you what the operating rhythm underneath them would have looked like. So we reverse-engineered it, not as history but as a worked example of turning a cascade into quarters.

The pivotal-condition quarter. Before any relaunch, the whole bet hangs on one doubtful condition: will mass-retail shoppers pay a prestige price? A real OKR here is a discovery bet run outside the scorecard: Objective, prove women 35 to 50 will pay $18.99 at mass; Key Result, willingness-to-pay validated in live test markets, not survey intent. Fail this and nothing downstream is funded.

The capability quarter. The How to Win needs the invented “technical marketer” role and the R&D-to-beauty-press bridge. That is a capability-building OKR in the Strategic lane, and the honest Key Result is not “role hired” but the capability cashing out: dermatologist claims landing in beauty-editor coverage that shifts trial.

The compelling-action quarter. Only now does the KR set become the behaviour Martin says is the only judge: repeat purchase, price held without promotion, share taken from prestige counters rather than from Olay's own older line. The strategy is proving true on the customer's behaviour, which is the only evidence that counts.

Read this way, Olay is not a story about bravery. It is a story about sequencing bets so the riskiest condition is tested first and the money follows the evidence. That sequence is exactly what our methodology installs, and it is the part the famous retelling leaves out.

One line to keep: Olay was not a bold bet; it was a well-sequenced one, and sequence is a goal-system's job.